RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivoDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Department of Applied Physics, Nanostructure Physics, Kungliga Tekniska Högskolan Royal Institute of Technology, Albanova University Center, Stockholm, Sweden.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Research Programmes Unit, Genome-Scale Biology, University of Helsinki, Finnish Cancer Institute, Helsinki, Finland.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kiev, Ukraine.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Cell Profiling Facility, Science for Life Laboratory, Kungliga Tekniska Högskolan Royal Institute of Technology, Stockholm, Sweden.
Laboratoire Interdisciplinaire de Physique, Université Joseph Fourier (Grenoble 1), Saint Martin d'Hères Cedex 9, France.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2017 (English)In: Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, E-ISSN 1091-6490, Vol. 114, no 8, p. E1413-E1421Article in journal (Refereed) Published
Abstract [en]
Fibroblasts are a main player in the tumor-inhibitory microenvironment. Upon tumor initiation and progression, fibroblasts can lose their tumor-inhibitory capacity and promote tumor growth. The molecular mechanisms that underlie this switch have not been defined completely. Previously, we identified four proteins over-expressed in cancer-associated fibroblasts and linked to Rho GTPase signaling. Here, we show that knocking out the Ras homolog family member A (RhoA) gene in normal fibroblasts decreased their tumor-inhibitory capacity, as judged by neighbor suppression in vitro and accompanied by promotion of tumor growth in vivo. This also induced PC3 cancer cell motility and increased colony size in 2D cultures. RhoA knockout in fibroblasts induced vimentin intermediate filament reorganization, accompanied by reduced contractile force and increased stiffness of cells. There was also loss of wide F-actin stress fibers and large focal adhesions. In addition, we observed a significant loss of a-smooth muscle actin, which indicates a difference between RhoA knockout fibroblasts and classic cancer-associated fibroblasts. In 3D collagen matrix, RhoA knockout reduced fibroblast branching and meshwork formation and resulted in more compactly clustered tumor-cell colonies in coculture with PC3 cells, which might boost tumor stem-like properties. Coculturing RhoA knockout fibroblasts and PC3 cells induced expression of proinflammatory genes in both. Inflammatory mediators may induce tumor cell stemness. Network enrichment analysis of transcriptomic changes, however, revealed that the Rho signaling pathway per se was significantly triggered only after coculturing with tumor cells. Taken together, our findings in vivo and in vitro indicate that Rho signaling governs the inhibitory effects by fibroblasts on tumor-cell growth.
Place, publisher, year, edition, pages
The National Academy of Sciences , 2017. Vol. 114, no 8, p. E1413-E1421
Keywords [en]
Rho GTPases, RhoA, cancer-associated fibroblasts, tumor-inhibitory capacity, cytoskeleton
National Category
Basic Cancer Research
Identifiers
URN: urn:nbn:se:oru:diva-124218DOI: 10.1073/pnas.1621161114ISI: 000395099500014PubMedID: 28174275Scopus ID: 2-s2.0-85013441081OAI: oai:DiVA.org:oru-124218DiVA, id: diva2:2004120
Funder
Swedish Research Council, VR 2015-02410Swedish Cancer Society, CF 15 0591Stiftelsen Syskonen Svenssons Stiftelse för Medicinsk Forskning
Note
This study was supported by grants from the Swedish Research Council and the Swedish Cancer Society. Bioinformatics support from National Bioinformatics Infrastructure Sweden is gratefully acknowledged. A.K.B.G. was supported by the Syskonen Svenssons Foundation and Ollie and Elof Ericssons Foundation. T.P., V.K., and H.G. were supported by fellowships by a matching grant jointly awarded by the Concern Foundation, Los Angeles, and the Cancer Research Institute, New York. A.A. was supported by Emil och Wera Cornells Stiftelse. R.J.L. was supported by the Dutch Cancer Society Grant UU 2012-5667.
2025-10-062025-10-062026-01-23Bibliographically approved